Biotech giant Biogen said Thursday that it achieved in $1.6 million in sales from its controversial Alzheimer’s drug last month after it was endorsed by the Food and Drug Administration prior in June.

The drug, which is marketed as Aduhelm, is the main new treatment for Alzheimer’s in around 18 years and the principal that specialists are trusting won’t simply diminish side effects however focus on the underlying disease.

The company said in its second-quarter income report that the drug, which was endorsed by the FDA on June 7, did $1.6 million in sales before the finish of the quarter, which was June 30.

The company’s income from Aduhelm is modest now, yet the drug has as of late been carried out. The company announced absolute income of nearly $2.8 billion for the quarter, down 25% from a year sooner.

The company said it anticipates that Aduhelm should keep on contributing modest income this year, with an increase from there on.

Biogen has slapped a $56,000-per-year sticker price on Aduhelm, shocking some Alzheimer’s advocates and surprisingly bringing up issues among Wall Street investigators.

The drug’s endorsement by the FDA carried desire to the in excess of 6 million Americans living with Alzheimer’s — albeit a few specialists protested the endorsement, saying there’s insufficient evidence to show it’s really viable.

Three researchers on a board prompting the FDA supposedly surrendered after the drug’s endorsement.

“This may be the most exceedingly terrible endorsement choice that the FDA has made that I can recollect,” Dr. Aaron Kesselheim said, as indicated by the news.

Notwithstanding concerns, last month a Rhode Island man turned into the principal patient to get a bonding of the drug.

Furthermore, questions have since been raised about whether the company assumed a part in affecting interior FDA considerations.

Recently, the FDA’s acting commissioner Janet Woodcock approached the autonomous Office of the Inspector General to examine whether chiefs from Biogen met with FDA staff outside of formal correspondence.

“There keep on being concerns raised … in regards to contacts between agents from Biogen and FDA during the audit process, including some that may have happened outside of the formal correspondence process,” Woodcock wrote in a letter presented Friday on acting Inspector General Christi Grimm.